Haleon PLC Total Voting Rights and Capital

RNS Number : 2704G

Haleon PLC

30 September 2024

 

 

 

Haleon plc: Total Voting Rights and Capital

 

30 September 2024: As at 30 September 2024 the total number of shares issued by Haleon plc ("Haleon" or the "Company") with rights to vote is 9,133,887,197 ordinary shares of £0.01 each. There are no ordinary shares held in Treasury.

 

The figure above may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules of the Financial Conduct Authority.

 

Notifiable interests in Haleon may be sent to: [e-mail]

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TVRURAARSVUKOAR